With $58M in hand, the start­up team at Pan­dion sets their sights on a next-gen ap­proach to im­munol­o­gy

An­tho­ny Coyle start­ed Pfiz­er’s Cen­ters for Ther­a­peu­tic In­no­va­tion with an eye to chang­ing the way the phar­ma gi­ant went about the busi­ness of drug dis­cov­ery. And then af­ter leav­ing last sum­mer and join­ing the great mi­gra­tion out of Big Phar­ma, he switched in­to a new role as biotech CEO — where he gets to take a more hands-on role in that strug­gle.

Coyle is at the helm of a new start­up called Pan­dion Ther­a­peu­tics, one of the lat­est ar­rivals in the bustling Cam­bridge, MA hub, where Po­laris seed­ed a group of about 12 re­searchers who have been look­ing to take some of the many lessons learned from im­muno-on­col­o­gy and then re­verse en­gi­neer­ing the tech­nol­o­gy for an­ti-in­flam­ma­to­ry or au­toim­mune drugs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER